{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T08:36:08Z","timestamp":1648802168847},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1992,1,1]],"date-time":"1992-01-01T00:00:00Z","timestamp":694224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/bf00685091","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T14:40:01Z","timestamp":1101652801000},"page":"81-84","source":"Crossref","is-referenced-by-count":3,"title":["Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Yoshikuni","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"1215","volume":"70","author":"JF Belliveau","year":"1986","unstructured":"Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, O'Leary GP Jr, Griffin H, Phaneuf MA, O'Rourke A, Calabresi P (1986) Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urinary platinum excretion. Cancer Treat Rep 70: 1215","journal-title":"Cancer Treat Rep"},{"key":"CR2","first-page":"10","volume":"16","author":"PA Bunn Jr","year":"1989","unstructured":"Bunn PA Jr (1989) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16: 10","journal-title":"Semin Oncol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0277-5379(85)90220-2","volume":"21","author":"J Carmichael","year":"1985","unstructured":"Carmichael J, Gregor A, Cornbleet MA, Allan SG, Mcintyre MA, Grant IWB, Compton GK, Leonard RCF, Smyth JF (1985) Cis-platinum and vindesine in combination in the treatment of non-small cell lung cancer. Eur J Cancer Clin Oncol 21: 811","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.1985.3.2.176","volume":"3","author":"HM Dhindra","year":"1985","unstructured":"Dhindra HM, Valdivieso M, Carr DT, Chiuten DF, Farha CP, Murphy WK, Spitzer G, Umsawasdi T (1985) Randomized trial of three combinations of cisplatin with vindesine and\/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 3: 176","journal-title":"J Clin Oncol"},{"key":"CR5","first-page":"3091","volume":"33","author":"B Drewinko","year":"1973","unstructured":"Drewinko B, Brown BW, Gottlieb JA (1973) The effect ofcis-diamminedichloroplatinum(II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33: 3091","journal-title":"Cancer Res"},{"key":"CR6","first-page":"5221","volume":"49","author":"K Eguchi","year":"1989","unstructured":"Eguchi K, Sasaki S, Tamura T, Sasaki Y, Shinkai T, Yamada K, Soejima Y, Fukuda M, Fujiwara Y, Kunitou H, Tobinai K, Ohtsu T, Suemasu K, Takaku F, Saijo N (1989) Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN 8601) in patients with advanced malignancy. Cancer Res 49: 5221","journal-title":"Cancer Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.1986.4.7.1037","volume":"4","author":"LH Einhorn","year":"1986","unstructured":"Einhorn LH, Loeher PJ, Williams S, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S (1986) Random prospective study of vindensine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037","journal-title":"J Clin Oncol"},{"key":"CR8","first-page":"1038","volume":"4","author":"M Fukuoka","year":"1990","unstructured":"Fukuoka M, Ariyoshi Y, Furuse K, Niitani H, Motomiya M, Hasegawa K, Tominaga K, Kuriyama T, Yoshida K, Kimura H, Kurita Y, Nakajima S, Nakai J, Ota M, Yamamoto H, Ota K (1990) Effect of recombinant human G-CSF (rG\u00b7CSF) in patients with non-small cell lung cancer (NSCLC) treated with combination chemotherapy of mitomycin C, vindesine, and cisplatin (MVP chemotherapy). Biotherapy 4: 1038","journal-title":"Biotherapy"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.7326\/0003-4819-95-4-414","volume":"95","author":"RJ Gralla","year":"1981","unstructured":"Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414","journal-title":"Ann Intern Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"63","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 63: 457","journal-title":"J Am Stat Assoc"},{"key":"CR11","first-page":"387","volume":"69","author":"MG Kris","year":"1985","unstructured":"Kris MG, Gralla RJ, Kalman LA, Kelsen DP, Casper ES, Burke MT, Groshen S, Cibas IR, Bagin R, Heelan RT (1985) Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69: 387","journal-title":"Cancer Treat Rep"},{"key":"CR12","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163","journal-title":"Cancer Chemother Rep"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF00434345","volume":"14","author":"Y Matsushima","year":"1985","unstructured":"Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N (1985) Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14: 104","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogatraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207","journal-title":"Cancer"},{"key":"CR15","doi-asserted-by":"crossref","unstructured":"Mori K, Saito Y, Tominaga K (1992) Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer. Am J Clin Oncol (in press)","DOI":"10.1097\/00000421-199208000-00015"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1378\/chest.89.4_Supplement.225S","volume":"89","author":"CF Mountain","year":"1986","unstructured":"Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225","journal-title":"Chest"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF02994086","volume":"26","author":"Y Saito","year":"1990","unstructured":"Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N (1990) Phase II study of 5-day continuous infusion ofcis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26: 389","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR18","first-page":"945","volume":"69","author":"T Shinkai","year":"1985","unstructured":"Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H (1985) Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 69: 945","journal-title":"Cancer Treat Rep"},{"key":"CR19","first-page":"89","volume":"21","author":"JB S\u00f8rensen","year":"1988","unstructured":"S\u00f8rensen JB, Clerici M, Hansen HH (1988) Single-agent chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 21: 89","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/bjc.1990.135","volume":"61","author":"RL Woods","year":"1990","unstructured":"Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1990) A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685091\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:12Z","timestamp":1554459012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992]]}},"alternative-id":["BF00685091"],"URL":"https:\/\/doi.org\/10.1007\/bf00685091","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992]]}}}